The Latest Breaking News from Clorox

Over the past 3 months, 9 analysts have published their opinion on Clorox (NYSE:CLX) stock. These analysts are typically employed by large Wall Street banks and tasked with understanding a company's business to predict how a stock will trade over the upcoming year.

The shares of Clorox (CLX) have tumbled more than 14% in price on the company’s worse-than-expected earnings release and diminished full-year guidance. The company is currently grappling with inflationary pressures and supply disruptions, which are negatively impacting its margins. So, with Clorox’s 44-year history of consecutive dividend growth, is the…

Clorox’s health and wellness sales fell 21% year-over-year in the quarter ending Dec. 31.

Clorox (NYSE:CLX) has observed the following analyst ratings within the last quarter:

Pulled from Benzinga Pro data, Clorox (NYSE:CLX) posted Q2 earnings of $72.00 million, an increase from Q1 of 49.65%. Sales dropped to $1.69 billion, a 6.37% decrease between quarters.

Clorox (NYSE:CLX) reported its Q2 earnings results on Thursday, February 3, 2022 at 04:15 PM. Here's what investors need to know about the announcement.

If history is any guide, there may be good fortune ahead for shares of Clorox (NYSE:CLX). A so-called "golden cross" has formed on its chart and, not surprisingly, this could be bullish for the stock.

Credit Suisse analyst Kaumil Gajrawala downgraded Clorox Co (NYSE:CLX) to Underperform from Neutral with a $160 price target. The analyst thinks a large portion of Clorox's growth during the first phase of the pandemic came from categories that are now declining. If consumption continues to revert toward pre-pandemic levels, $500 million in company sales may…

Monday marks the last chance for investors to receive the next dividend payout from Clorox.